BACKGROUND: Hepatitis C virus infection is one of the main causes of chronic liver disease, with high death rates. The aim here was to analyze case outcomes, sociodemographic and clinical characteristics and spatial distribution among patients diagnosed with hepatitis C in the city of Santa Cruz do Sul (RS), Brazil. DESIGN AND SETTING: Cross-sectional study on 200 cases of hepatitis C in Santa Cruz do Sul that were notified between 2002 and 2015. METHODS: Secondary data including sociodemographic and clinical variables and type of outcome (death, follow-up, abandonment or clinical cure) were gathered. The spatial distribution analysis on hepatitis C virus cases according to outcome was based on information regarding residential address. RESULTS: 58.5% of the patients were 41 years of age and over, 67% were males and 92.5% had the chronic form of the disease. The most frequent transmission route was illicit drug injection (29%); 15.1% of the patients presented coinfection with the human immunodeficiency virus (HIV). Regarding outcomes, 31% achieved clinical cure, 10% died and 20% abandoned follow-up. The cases studied were mainly located in regions of the city characterized by lower socioeconomic status, with high frequency of places used for drug trafficking. CONCLUSION: The population consisted of adults aged 41 years and over, mostly with chronic hepatitis C. The most common transmission routes were illicit drug injection and blood transfusions. There were high rates of HIV coinfection and abandonment of disease monitoring and predominance of cases in neighborhoods with low socioeconomic status.
INTRODUCTION
The hepatitis C virus (HCV) is one of the leading causes of chronic liver disease worldwide and is characterized as a silent disease that is difficult to identify in most patients. 1, 2 Approximately 15%-45% of infected individuals spontaneously clear the virus within six months of infection without any treatment, and the remaining 55%-85% of them may progress to persistent chronic infection. It has been estimated that the risk of developing cirrhosis within 20 years is 15%-30% in those with chronic HCV infection, and the risk of developing hepatocellular carcinoma is 1%-4% per year. 3, 4 At a global level, around 71 million people have HCV, with approximately 399,000 deaths annually. 5 In Brazil, the data show that the numbers of deaths due to HCV have been increasing over time in all regions. Between 2000 and 2015, 46,314 deaths related to HCV were identified. 1 The southern region presented a coefficient of mortality due to HCV as the underlying cause of death for 1.5/100,000 inhabitants. In the state of Rio Grande do Sul (RS), this coefficient was 2.8/100,000 inhabitants, which was almost three times larger than the national mean for the same period. 1 The data on the extent and spatial distribution of HCV outcomes in the city of Santa Cruz do Sul (RS) is limited, which thus highlights the usefulness of the present study.
The main route for HCV transmission is the parenteral route, through direct or percutaneous contact with contaminated blood. Additionally, it is also transmitted through sexual activity and the vertical route. [1] [2] [3] The groups at greatest risk of contracting HCV are illicit drug users, individuals with piercings and tattoos that were made using contaminated tools, HIV-positive patients, individuals who received blood before 1992, healthcare professionals and patients undergoing hemodialysis. [1] [2] [3] Other less common forms of contamination are the parenteral route, which may occur through medical, dental, manicure and acupuncture procedures; and sharing of objects within the household. 6, 7 HCV prevention and control depends on a complex assessment of HCV infection, which involves correlation of risk factors and estimation of factors that accelerate disease progression. 8, 9 Because there is no vaccine for HCV, or any type of post-exposure prophylaxis, proper epidemiological evaluation is essential for planning primary HCV prevention in any population. Follow-up of HCV-positive individuals by the healthcare team is of utmost importance, rather than sporadic medical evaluation. Such follow-up is required in order to establish what the treatment should be and to ensure adherence to treatment. HCV treatment is available free of charge through the Brazilian National Health System (SUS). 10 In the light of this situation, the objective of the present study was to analyze case outcomes, sociodemographic and clinical characteristics and spatial distribution among HCV cases that were notified between 2002 and 2015 in the city of Santa Cruz do Sul (RS), Brazil. Situations in which patients had undetectable levels of HCV-RNA four weeks after treatment were considered to constitute clinical cure. Patients whose cases had been notified to SINAN but for whom there were no data in electronic records, SIM or GAL were considered to be unlocatable.
METHODS
The spatial distribution of HCV cases was determined based on information regarding the residential address found in SINAN.
The distribution analysis on the cases was performed using the rep- format. These points were inserted as an overlay in the QGIS, so that they could be located. The final layouts of the maps were also produced using the QGIS software.
The data were input and analyzed using the SPSS software, version 23.0. A descriptive analysis was carried out, which included investigation of the frequency distribution of sociodemographic, clinical and outcome variables. The data were presented as absolute numbers, frequencies and/or means.
This project was approved by the Research Ethics Committee It was possible to describe the spatial distribution of HCV cases in relation to 172 patients (86%). The numbers of HCV cases were higher in regions of the municipality with lower socioeconomic status and high frequency of places used for drug trafficking, and in the regional prison (Figure 1) .
DISCUSSION
This study population predominantly comprised adult individuals aged 41 years and over. The reported transmission routes were, most frequently, illicit drugs and blood transfusions.
Among all the cases, 92.5% had chronic hepatitis, 52% had genotype 1, 10% died, 31% achieved clinical cure and 15.1% were coinfected with HIV.
In a study carried out among HCV-positive individuals who were attended at a public service in Porto Alegre, Brazil, it was found that the mean age of the individuals assessed was 40.1 years. 13 Other studies have also shown higher numbers of cases among individuals older than 40 years of age. 13, 14 Similar results were observed in our study. The diagnosis of hepatitis C is more frequent in adulthood and among the elderly, given that it is a silent and chronic disease, and because these individuals may have undergone some type of surgery with inadequately sterilized instruments and unsafe blood transfusions before the year 1993, when there was no screening for hepatitis C in blood banks yet. 14, 15 Regarding sex, the hepatitis C cases were predominant among male individuals (67%), thus corroborating other studies. 13, 16 In Brazil, 106,637 HCV cases occurred among males between 1999 and 2015, representing 58.5% of all cases. 1 The higher prevalence of hepatitis C virus infection among males can be explained by their exposure to risk factors, or by the fact that the diagnosis of HCV is made when men are blood donation volunteers. 15 HCV infection affects both men and women, but there are no comprehensive studies confirming that men are more vulnerable to this infection. 15 The main routes of HCV transmission have been found to be illicit drugs, blood transfusions (mainly before 1992), sharing of materials for drug use, lack of personal hygiene and presence of tattoos and piercings. 17, 18 The risk of sexual transmission is low, but recent data have shown that promiscuous male homosexual activity is associated with HCV infection. 18 In the present study, 29% of the patients reported drug use and 12.5% had had blood transfusions, but the year of the blood transfusion was not mentioned. 19 In the present study, 15.1% of the individuals had HCV/HIV coinfection. About 2.3 million people living with HIV around the world are coinfected with HCV. 20 The HCV/HIV coinfection rate for Brazil between 2007 and 2016 was 9.8% and it varied according to the region. 1 The southern region had the highest coinfection rate in Brazil (13.3%), and this was similar to what was observed in the present study. In cases in which coinfection occurs, the host's immune response is impaired and the prognosis for both infections is worsened: liver impairment is accelerated, with progression to cirrhosis, liver failure and liver carcinoma, which can lead to the death of the infected individual. 19, 21 Antiretroviral therapy, which improves the survival of HIV-infected patients, may contribute towards liver injury and lead to hepatotoxicity in cases of coinfection, thereby accentuating the liver injury caused by the hepatitis virus.
The risks of hepatotoxicity in coinfected patients are three to four times higher than in non-infected patients, due to liver disorders. 21 Regarding the form of the disease, 92.5% of the individuals in the present study had the chronic form and 10% of them died. A systematic review of the literature suggested that approximately 130-150 million people are living with chronic hepatitis C. 22 In Brazil, between 1999 and 2016, more than 155,000 cases of chronic HCV cases were confirmed. 1 Between 1990 and 2013, the number of deaths worldwide due to viral hepatitis increased from 0.89 million to 1.45 million. 23 In the absence of treatment, 20-30% of hepatitis B virus (HBV) and HCV-infected individuals will develop hepatocellular carcinoma or cirrhosis. It has been estimated that this will lead to 19 million deaths between 2015 and 2030 (11.8 million due to HBV and 7.2 million due to HCV) around the world. 23 In the present study, 22 cases (11%) developed cirrhosis or hepatocellular cancer.
Treatment for hepatitis is available free of charge through the Brazilian public health system (SUS) and has the purpose of reducing the risk of developing cirrhosis and liver carcinoma. The most widely used pharmacological treatment for HCV was for many years based on a combination of interferon and ribavirin. 24 Treatment regimens based on interferon may be problematic because of the high frequency of adverse effects and the inconvenience of weekly injections. Thus, their effectiveness may be limited especially among patients whose clinical condition is more severe. 24, 25 Recently, the introduction of therapeutic regimens including new drugs such as sofosbuvir and daclatasvir has shown positive results regarding HCV treatment. 26 Among the patients analyzed here, it was seen that 31% presented clinical cure, regardless of the thera- recently treated, SVR rates may reach values greater than 80%. 27 One limitation of this study was indeed the impossibility of evaluating the therapeutic regimens used individually. A total of 33% of the patients were considered to be unlocatable in any of the public information systems investigated. Some of these patients may have sought treatment within the private sector.
Among the patients of the present study, 45 (22.5%) are still being followed up, and 40 (20%) abandoned their treatment. HCV is a disease that requires discipline among patients and understanding from healthcare professionals, and situations that can significantly interfere with the success of follow-up and treatment adherence need to be identified rapidly. 27 Thus, it is crucial that healthcare professionals should establish a solid relationship with their patients. 10, 21 To establish proper treatment for patients with chronic HCV, it is extremely important that their medical records, anamnesis and physical examination should be rigorously completed and that they are included within the routine of screening and referral services.
The same is true regarding filling out forms that are used in disease notification and requests for examinations. Adherence to healthcare services among patients with chronic hepatitis C is essential, for the healthcare strategy to be successful. 27 During the pretreatment period, it is also necessary to make a careful evaluation of patients' comorbidities and coinfections caused by HBV and HIV, along with their clinical, psychiatric and social conditions. 21, 28 Because of the pathophysiological characteristics of chronic HCV infection, at least four consultations per year are required. This routine should be individualized among patients for whom therapy was recently started or in situations in which the risk of adverse events requires priority care. 21 Genotype 1 (52%) was most prevalent in the present study, which confirms that in RS and Brazil, genotype 1 is the one most frequently identified. This is also the genotype that is the most resistant and the most difficult to treat. 14 HCV genotype 1 is most prevalent worldwide (49.1%), followed by genotypes 3 (17.9%), 4 (16.8%) and 2 (11.0%). 29 Silva et al. evaluated genotype distribution in a population of more than 1,500 patients living in the states of RS and SC. These data confirmed that genotypes 1 (53.9%) and 3 (40.7%) were most prevalent in southern Brazil, with frequencies that were similar to those found in the present study. 30 According to the assessment of the geographical distribution of HCV cases, there was higher prevalence of cases in the districts where the populations showed the highest levels of social vulnerability and in a prison where 12 cases (6%) were identified. These districts have low socioeconomic levels and include many places that are used for drug trafficking. Oliveira et al. carried out a geoprocessing analysis on HCV cases in São Paulo and found that HCV infection was associated with low socioeconomic level. 23 One hypothesis that corroborates the greater presence of HCV cases in regions with low socioeconomic status could be that such individuals lack knowledge about HCV infection routes, such as the sharing of razors, use of pliers, tattooing with non-sterile material, unprotected sexual intercourse and use of needles shared among drug users. [2] [3] [4] [5] [6] HCV infection and other forms of viral hepatitis are diseases that have an impact on public health worldwide. Although many data suggest that HCV infection could be eliminated over the next 15-20 years, good understanding of HCV infections is still required in order to develop strategies for preventing new infections. 31 In this regard, support for health promotion and establishment of surveillance, prevention and control measures for these diseases is crucial for improving patients' quality of life and decreasing disease transmission.
CONCLUSION
This population of HCV cases that were diagnosed and notified between 2002 and 2015 in the municipality of Santa Cruz do Sul, was characterized by adult individuals aged 41 years and over, who mostly had chronic hepatitis C and were undergoing treatment.
The main transmission routes were illicit drugs and blood transfusions. There were high rates of HIV coinfection and abandonment of disease monitoring, and the cases were predominantly in neighborhoods with low socioeconomic status. In this regard, the present study helps to alert the health authorities about the importance of this disease and the need to implement coping strategies, while also encouraging other studies, with the aim of improving the understanding of the HCV infection situation in other locations.
